Biofilm-dependent airway infections: a role for ambroxol?

Area of Science:

• Microbiology
• Pharmacology
• Pulmonology

Background:

• Biofilms significantly contribute to acute and chronic airway infections, including ventilator-associated pneumonia and cystic fibrosis.
• Microbial growth in biofilms leads to multidrug resistance, complicating treatment strategies for airway infections.
• Emerging evidence suggests biofilm involvement in chronic obstructive pulmonary disease and bronchiectasis.

Purpose of the Study:

• To review recent evidence on ambroxol's anti-biofilm properties.
• To discuss additional pharmacological benefits of ambroxol in biofilm-dependent airway infections.
• To explore ambroxol's potential as a therapeutic agent for challenging respiratory conditions.

Main Methods:

• Review of existing scientific literature on ambroxol and biofilms.
• Analysis of studies detailing ambroxol's anti-inflammatory mechanisms.
• Examination of research on ambroxol's effects on mucociliary clearance and airway epithelium ion transport.

Main Results:

• Ambroxol demonstrates specific anti-biofilm properties.
• Ambroxol exerts anti-inflammatory effects by inhibiting neutrophil activity.
• Ambroxol enhances mucociliary clearance by modulating airway epithelium ion channels and transporters.

Conclusions:

• Ambroxol possesses multiple pharmacological properties beneficial for biofilm-dependent airway infections.
• Ambroxol's anti-biofilm, anti-inflammatory, and mucociliary clearance effects suggest therapeutic potential.
• Further clinical investigation is essential to validate ambroxol's efficacy in treating these respiratory diseases.